ObsEva SA (OBSV) Given Average Recommendation of “Buy” by Brokerages

Shares of ObsEva SA (NASDAQ:OBSV) have received a consensus rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $23.00.

Several brokerages have issued reports on OBSV. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of ObsEva SA in a research report on Wednesday, October 4th. Zacks Investment Research lowered shares of ObsEva SA from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. Royal Bank Of Canada began coverage on shares of ObsEva SA in a research report on Thursday, September 14th. They set an “outperform” rating and a $22.00 target price for the company. Finally, Leerink Swann reiterated an “outperform” rating and set a $18.00 target price on shares of ObsEva SA in a research report on Wednesday, August 16th.

ObsEva SA (OBSV) opened at 8.69 on Monday. The firm’s market capitalization is $257.49 million. The company’s 50-day moving average is $7.73 and its 200-day moving average is $7.73. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.69.

ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings data on Tuesday, August 15th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.13). During the same quarter in the prior year, the company posted ($0.30) EPS. Analysts forecast that ObsEva SA will post ($2.38) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/10/09/obseva-sa-obsv-given-average-recommendation-of-buy-by-brokerages.html.

A number of institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its position in ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after purchasing an additional 20,411 shares during the last quarter. Sectoral Asset Management Inc lifted its position in ObsEva SA by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after purchasing an additional 137,331 shares during the last quarter. VHCP Management II LLC bought a new stake in ObsEva SA during the second quarter valued at approximately $1,283,000. UBS Oconnor LLC bought a new stake in ObsEva SA during the first quarter valued at approximately $1,017,000. Finally, Citadel Advisors LLC bought a new stake in ObsEva SA during the first quarter valued at approximately $937,000. Institutional investors and hedge funds own 48.46% of the company’s stock.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medic

Several brokerages have issued reports on OBSV. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of ObsEva SA in a research report on Wednesday, October 4th. Zacks Investment Research lowered shares of ObsEva SA from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. Royal Bank Of Canada began coverage on shares of ObsEva SA in a research report on Thursday, September 14th. They set an “outperform” rating and a $22.00 target price for the company. Finally, Leerink Swann reiterated an “outperform” rating and set a $18.00 target price on shares of ObsEva SA in a research report on Wednesday, August 16th.

ObsEva SA (OBSV) opened at 8.69 on Monday. The firm’s market capitalization is $257.49 million. The company’s 50-day moving average is $7.73 and its 200-day moving average is $7.73. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.69.

ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings data on Tuesday, August 15th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.13). During the same quarter in the prior year, the company posted ($0.30) EPS. Analysts forecast that ObsEva SA will post ($2.38) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/10/09/obseva-sa-obsv-given-average-recommendation-of-buy-by-brokerages.html.

A number of institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its position in ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after purchasing an additional 20,411 shares during the last quarter. Sectoral Asset Management Inc lifted its position in ObsEva SA by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after purchasing an additional 137,331 shares during the last quarter. VHCP Management II LLC bought a new stake in ObsEva SA during the second quarter valued at approximately $1,283,000. UBS Oconnor LLC bought a new stake in ObsEva SA during the first quarter valued at approximately $1,017,000. Finally, Citadel Advisors LLC bought a new stake in ObsEva SA during the first quarter valued at approximately $937,000. Institutional investors and hedge funds own 48.46% of the company’s stock.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply